C Orkin1, S Flanagan1, E Wallis1, G Ireland2, R Dhairyawan3, J Fox4, R Nandwani5, R O'Connell1, M Lascar1, J Bulman6, I Reeves7, A Palfreeman8, G R Foster9, K Ahmad10, J Anderson2, C Y W Tong11, S Lattimore2. 1. Ambrose King Centre, Barts Health NHS Trust, Royal London Hospital, London, UK. 2. Public Health England, London, UK. 3. Sexual Health Department, Barking, Havering and Redbridge NHS Trust, London, UK. 4. Sexual Health Department, Kings College Hospital, London, UK. 5. Sexual Health Department, NHS Greater Glasgow and Clyde, Glasgow, UK. 6. Sexual Health Department, Leeds Teaching Hospital, Leeds, UK. 7. Sexual Health Department, Homerton University Hospital, London, UK. 8. Sexual Health Department, University Hospital of Leicester NHS Trust, Leicester, UK. 9. Hepatology Department, Queen Mary University London, London, UK. 10. Emergency Department, Barts Health NHS Trust, Royal London Hospital, London, UK. 11. Virology Department, Barts Health NHS Trust, Royal London Hospital, London, UK.
Abstract
OBJECTIVES: Routine HIV screening is recommended in those UK hospitals and primary care settings where the HIV prevalence is > 0.2%. For hepatitis B virus (HBV) and hepatitis C virus (HCV), however, testing is targeted at at-risk groups. We investigated the prevalence of these blood-borne viruses (BBVs) during a routine testing pilot in UK Emergency Departments (EDs). METHODS: During the "Going Viral" campaign (13-19 October 2014), nine UK EDs in areas of high HIV prevalence offered routine tests for HIV, HBV and HCV to adults having blood taken as part of routine care. Patients who tested positive were linked to care. RESULTS: A total of 7807 patients had blood taken during their ED visit; of these, 2118 (27%) were tested for BBVs (range 9-65%). Seventy-one BBV tests were positive (3.4%) with 32 (45.1%) new diagnoses. There were 39 HCV infections (15 newly diagnosed), 17 HIV infections (six newly diagnosed), and 15 HBV infections (11 newly diagnosed). Those aged 25-54 years had the highest prevalence: 2.46% for HCV, 1.36% for HIV and 1.09% for HBV. Assuming the cost per diagnosis is £7, the cost per new case detected would be £988 for HCV, £1351 for HBV and £2478 for HIV. CONCLUSIONS: In the first study in the UK to report prospectively on BBV prevalence in the ED, we identified a high number of new viral hepatitis diagnoses, especially hepatitis C, in addition to the HIV diagnoses. Testing for HIV alone would have missed 54 viral hepatitis diagnoses (26 new), supporting further evaluation of routine BBV testing in UK EDs.
OBJECTIVES: Routine HIV screening is recommended in those UK hospitals and primary care settings where the HIV prevalence is > 0.2%. For hepatitis B virus (HBV) and hepatitis C virus (HCV), however, testing is targeted at at-risk groups. We investigated the prevalence of these blood-borne viruses (BBVs) during a routine testing pilot in UK Emergency Departments (EDs). METHODS: During the "Going Viral" campaign (13-19 October 2014), nine UK EDs in areas of high HIV prevalence offered routine tests for HIV, HBV and HCV to adults having blood taken as part of routine care. Patients who tested positive were linked to care. RESULTS: A total of 7807 patients had blood taken during their ED visit; of these, 2118 (27%) were tested for BBVs (range 9-65%). Seventy-one BBV tests were positive (3.4%) with 32 (45.1%) new diagnoses. There were 39 HCV infections (15 newly diagnosed), 17 HIV infections (six newly diagnosed), and 15 HBV infections (11 newly diagnosed). Those aged 25-54 years had the highest prevalence: 2.46% for HCV, 1.36% for HIV and 1.09% for HBV. Assuming the cost per diagnosis is £7, the cost per new case detected would be £988 for HCV, £1351 for HBV and £2478 for HIV. CONCLUSIONS: In the first study in the UK to report prospectively on BBV prevalence in the ED, we identified a high number of new viral hepatitis diagnoses, especially hepatitis C, in addition to the HIV diagnoses. Testing for HIV alone would have missed 54 viral hepatitis diagnoses (26 new), supporting further evaluation of routine BBV testing in UK EDs.
Authors: Jeanne Heil; Christian J P A Hoebe; Jochen W L Cals; Henriëtte L G Ter Waarbeek; Inge H M van Loo; Nicole H T M Dukers-Muijrers Journal: Ann Fam Med Date: 2018-01 Impact factor: 5.166
Authors: S Parry; N Bundle; S Ullah; G R Foster; K Ahmad; C Y W Tong; S Balasegaram; C Orkin Journal: Epidemiol Infect Date: 2018-04-17 Impact factor: 4.434
Authors: Joseph D Tucker; Kathrine Meyers; John Best; Karyn Kaplan; Razia Pendse; Kevin A Fenton; Isabelle Andrieux-Meyer; Carmen Figueroa; Pedro Goicochea; Charles Gore; Azumi Ishizaki; Giten Khwairakpam; Veronica Miller; Antons Mozalevskis; Michael Ninburg; Ponsiano Ocama; Rosanna Peeling; Nick Walsh; Massimo G Colombo; Philippa Easterbrook Journal: BMC Infect Dis Date: 2017-11-01 Impact factor: 3.090
Authors: Christina Greenaway; Iuliia Makarenko; Claire Nour Abou Chakra; Balqis Alabdulkarim; Robin Christensen; Adam Palayew; Anh Tran; Lukas Staub; Manish Pareek; Joerg J Meerpohl; Teymur Noori; Irene Veldhuijzen; Kevin Pottie; Francesco Castelli; Rachael L Morton Journal: Int J Environ Res Public Health Date: 2018-09-14 Impact factor: 3.390
Authors: Anna Maria Geretti; Harrison Austin; Giovanni Villa; Dan Hungerford; Colette Smith; Paula Davies; Jillian Williams; Apostolos Beloukas; Wojciech Sawicki; Mark Hopkins Journal: Sci Rep Date: 2018-10-17 Impact factor: 4.379